...
首页> 外文期刊>American Journal of Physiology >Recombinant human activated protein C improves endotoxemia-induced endothelial dysfunction: a blood-free model in isolated mouse arteries
【24h】

Recombinant human activated protein C improves endotoxemia-induced endothelial dysfunction: a blood-free model in isolated mouse arteries

机译:重组人类活化蛋白C改善内毒素血症诱导的内皮功能障碍:孤立小鼠动脉中的无血模型

获取原文
获取原文并翻译 | 示例

摘要

Recombinant human activated protein C (rhAPC) is one of the treatment panels for improving vascular dysfunction in septic patients. In a previous study, we reported that rhAPC treatment in rat endotoxemia improved vascular reactivity, although the mechanisms involved are still under debate. In the present study, we hypothesized that rhAPC may improve arterial dysfunction through its nonanticoagulant properties. Ten hours after injection of LPS in mice (50 mg/kg ip), aortic rings and mesenteric arteries were isolated and incubated with or without rhAPC for 12 h. Aortic rings were mounted in a myograph, after which arterial contractility and endothelium-dependent relaxation were measured in the presence or absence of nitric oxide synthase or cyclooxygenase inhibitors. Flow (shear stress)-mediated dilation with or without the above inhibitors was also measured in mesenteric resistance arteries. Protein expression was assessed by Western blotting. Lipopolysaccharide (LPS) reduced aortic contractility to KCl and phenylephrine as well as dilation to acetylcholine. LPS also reduced flow-mediated dilation in mesenteric arteries. In rhAPC-treated aorta and mesenteric arteries, contractility and endothelial responsiveness to vasodilator drug and shear stress were improved. rhAPC treatment also improved LPS-induced endothelial dysfunction; this effect was associated with an increase in the phosphorylated form of endothelial nitric oxide synthase and protein kinase B as well as cyclooxygenase vasodilatory pathways, thus suggesting that these pathways, together with the decrease in nuclear factor-kappaB activation and inducible nitric oxide synthase expression in the vascular wall, are implicated in the endothelial effect of rhAPC. In conclusion, ex vivo application of rhAPC improves arterial contractility and endothelial dysfunction resulting from endotoxemia in mice. This finding provides important insights into the mechanism underlying rhAPC-induced improvements on arterial dysfunction during septic shock.
机译:重组人活化蛋白C(rhAPC)是改善败血病患者血管功能障碍的治疗方法之一。在先前的研究中,我们报道了大鼠内毒素血症中的rhAPC治疗可改善血管反应性,尽管涉及的机制仍在争论中。在本研究中,我们假设rhAPC可以通过其非抗凝特性改善动脉功能障碍。在小鼠中注射LPS(50mg / kg ip)十小时后,分离主动脉环和肠系膜动脉,并在有或没有rhAPC的情况下孵育12小时。将主动脉环安装在肌动描记器中,然后在是否存在一氧化氮合酶或环氧合酶抑制剂的情况下测量动脉收缩性和内皮依赖性舒张。在肠系膜阻力动脉中也测量了有或没有上述抑制剂的流动(剪切应力)介导的扩张。通过蛋白质印迹评估蛋白质表达。脂多糖(LPS)降低了对KCl和去氧肾上腺素的主动脉收缩能力以及对乙酰胆碱的扩张作用。 LPS还减少了肠系膜动脉血流介导的扩张。在rhAPC处理的主动脉和肠系膜动脉中,对血管扩张药和剪切应力的收缩性和内皮反应性得到改善。 rhAPC治疗还改善了LPS诱导的内皮功能障碍。这种作用与内皮型一氧化氮合酶和蛋白激酶B磷酸化形式以及环加氧酶血管舒张途径的增加有关,因此表明这些途径与核因子-κB活化和诱导型一氧化氮合酶表达的降低有关。血管壁与rhAPC的内皮作用有关。总之,rhAPC的体外应用可改善小鼠内毒素血症引起的动脉收缩性和内皮功能障碍。该发现为败血性休克期间rhAPC引起的动脉功能障碍改善的潜在机制提供了重要的见识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号